2022
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A. Immune-checkpoint inhibitors for glioblastoma: what have we learned? Arquivos De Neuro-Psiquiatria 2022, 80: 266-269. PMID: 35976319, PMCID: PMC9491432, DOI: 10.1590/0004-282x-anp-2022-s129.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRecurrent glioblastomaBrain tumorsRandomized phase 3 trialCommon malignant primary brain tumorPost-treatment tumor samplesMalignant primary brain tumorSuccessful immunotherapeutic approachesPhase 3 trialPhase 1 studySelection of patientsT cell dysfunctionNew safety concernsHigh mutational burdenPrimary brain tumorsCheckpoint inhibitorsRadiographic responseImmunotherapeutic approachesPD-L1Survival improvementImmunologic responseTherapeutic optionsClinical trialsCNS microenvironmentCell dysfunction
2021
T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies
Jansen JA, Omuro A, Lucca LE. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies. Current Opinion In Neurology 2021, 34: 827-833. PMID: 34569985, PMCID: PMC8595795, DOI: 10.1097/wco.0000000000000988.Peer-Reviewed Original ResearchConceptsT cell dysfunctionTumor-infiltrating T cellsT cellsCell dysfunctionFuture immunotherapy strategiesCervical lymph nodesTumor-derived antigensImmune checkpoint blockadeCentral nervous systemHomeostatic brainSuccessful immunotherapyCheckpoint blockadeImmunotherapy strategiesLymph nodesTumor rejectionImmune surveillanceImmune responseMouse modelBrain tumorsLymphatic drainageNervous systemSolid tumorsDysfunctionSingle-cell RNA sequencingNatural history